All News
Why treatment of pre-RA isn't ready for prime time
The ACR Great Debate was on "To treat or not to treat in pre-RA?". What is the clinician to do?
Read Article
Imaging in PMR
Despite the fact that polymyalgia rheumatica is the most prevalent inflammatory rheumatic disease in those over 65 years of age, progress in its diagnosis, monitoring and management have failed to garner momentum in decades past.
However, ACR22 has fostered significant promise for its future.
Anifrolumab shows long-term promise in patients with lupus
Researchers report positive results from the first placebo-controlled long-term trial of anifrolumab—a human monoclonal antibody that targets the type I IFN receptor—in patients with lupus.
https://t.co/IlgEUKkMOv https://t.co/kpSt61d5Qx
Links:
Dr. John Cush RheumNow ( View Tweet)
Effect of voclosporin in class V lupus nephritis
Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
https://t.co/sH04dhBskS https://t.co/mUOrJKdYBF
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 - Day 1
https://t.co/GlEhTnKXm7 https://t.co/JFyMSpjFq3
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK vs TNF inhibitor Infections in RA
Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
https://t.co/ipD5ON7BJ7 https://t.co/rRD5wqHhFk
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Appraisal, Praise & Critique
Dr. Cush talks ACR22, the highs and the lows.
https://t.co/1SVr2LLOcG https://t.co/PqcMix7O1f
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective review of 265 ILD pts - 9.8% were ANCA positive (PR3, MPO). ANCA- oft called IPF. ANCA+ CTD-ILD and 65% evolved into AAV (29% AAV follwed ILD Dx). No lung diff betw Pos v Neg pts, but ANCA+ had more drugs, hosp. #ACR22 https://t.co/X6UfiawfmW https://t.co/BZpTsjYAFW
Links:
Dr. John Cush RheumNow ( View Tweet)
Breakthrough COVID infection in SLE during Omicron era
Dr. Yusof ( @Yuz6Yusof) talks with Dr. Amit Saxena about abstract #2081 at #ACR22
Abstract 2081: COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients....
https://t.co/0OFcHK2PLj https://t.co/2ULOfSZUqU
Links:
Dr. John Cush RheumNow ( View Tweet)
Opioids and Health Care Utilization in PsA and AS
Dr Aurelie Najm ( @AurelieRheumo) discusses Abstract 0402 presented at #ACR22. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS
https://t.co/trruZGyIVf https://t.co/8kj9vpKPlD
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Ted Mikuls has authored a Clinical practive review of Gout in this weeks New England Journal of Medicine - Congrats Ted! https://t.co/8MuC6upkOT https://t.co/zO4nZbWQ5A
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective review of 185 hospitalized AOSD pts (incidence 0.16 - 0.21/100K); Mean age 47 (70% female), mean ESR 55, CRP 12.26, ferritin 7141 WBC 12.15, anemia 23%. 24% ICU care & overall mortality was 3.2%. Ab#0829 #ACR22 https://t.co/eDRY4b3GAg https://t.co/3pt0ZH5QQH
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of PsA on Day 1
Dr. Rachel Tate ( @uptoTate) discusses the best PSA data presented 11/12 at #ACR22
https://t.co/i93CX7wic3 https://t.co/dQDOcIsu1P
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 - Day 2 Part III
RheumNow and its reporters review abstracts presented on Day 2 of #ACR22.
https://t.co/uUiX7s5Ajf https://t.co/0E5KSpOyyL
Links:
Dr. John Cush RheumNow ( View Tweet)
Survival and Mortality in RA: time to move away from “one-size fits all”?
Dr. Aurelie Najm ( @AurelieRheumo ) reviews Abstract #0246 at #ACR22.
https://t.co/O4dNzCZmmd https://t.co/cWUXEpduID
Links:
Dr. John Cush RheumNow ( View Tweet)
Exciting Data for SLE: Plenaries from #ACR22
Dr. Michael Putman ( @EBRheum ) shares SLE updates shared at #ACR22.
https://t.co/34HAvc2S8F https://t.co/xINo52fF2O
Links:
Dr. John Cush RheumNow ( View Tweet)
Can computers tell the difference between RA & PsA?
Dr. David Liew ( @drdavidliew) discusses Abstract 0242 presented at #ACR22. Abstract 0242: Neural Networks for Distinguishing RA from PsA by Using Magnetic Resonance Imaging
https://t.co/ZL5TYIdT6Q https://t.co/tZWIAl0rb0
Links:
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib vs Adalimumab in PsA using RAPID3
Dr. Catherine Sims ( @DrCassySims) discusses abstract 0192 presented at #ACR22. 0192: Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with PsA,
https://t.co/nRjgM45GdO https://t.co/MDqpW7ACXa
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Rheumatology Roundup w/ Drs. Kavanaugh & Cush
#1044 Combo Rx SpA
#0533 CCP spit
#1604 StopRA
#2251 Tofa & RA ILD
#0420 NSAID SpA
#002 CA in IIM
#0113 BTK Sjogrens
#L05 Prolia EOA
#0526 Pexivas
#1106 TCZ PMR
Video: https://t.co/JG3spEsYDD
Podcast: https://t.co/nbmeiGo2yt https://t.co/E7RDPTFsaS
Dr. John Cush RheumNow ( View Tweet)
Urinary Biomarkers in Lupus
Dr.Cush interviews Dr. Fava about Abstract 536 at #ACR22. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
https://t.co/3IfPdTMufb https://t.co/XVECG9mJri
Links:
Dr. John Cush RheumNow ( View Tweet)